| |
| | Health Care Renewal: An Update on the Tragic TGN 1412 Trial (Site not responding. Last check: 2007-10-08) |
 | | Our most recent post on the lack of transparency in the trial run by Parexel of TGN 1412, a drug developed by TeGenero, which left all six participants in intensive care with multi-organ system failure, was here. |
 | | According to TeGenero, the TGN 1412 leads to "pronounced T-cell activation and expansion." Thus, unlike some other monoclonal antibodies used to treat cancer, this drug was meant to change the settings, as it were, of the patient's immune system. |
 | | The drug TGN 1412, designed to fight leukaemia, rheumatoid arthritis and multiple sclerosis, was injected 15 times more quickly than when given to monkeys in animal studies, confidential documents have revealed. |
| www.pkblogs.com /hcrenewal/2006/03/update-on-tragic-tgn-1412-trial.html (936 words) |
|